DermTech(DMTK) - 2024 Q1 - Quarterly Results

Exhibit 99.1 • Cash, cash equivalents, restricted cash and short-term marketable securities were $42.4 million as of March 31, 2024. DERMTECH REPORTS FIRST-QUARTER 2024 FINANCIAL RESULTS -Average selling price (ASP) for the DermTech Melanoma Test (DMT) increased 24 percent year-over-year -Test revenue increased 7 percent versus the first quarter of 2023 SAN DIEGO – May 14, 2024 – DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomic ...